Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aee-788. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 6/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | BCR | P11274 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | ABL2 | P42684 | 1/20 | 1.00 |
| ▸ | NEK3 | P51956 | 1/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 1/20 | 1.00 |
| ▸ | LIMK2 | P53671 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aee-788 SCHEMBL29973591 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29478848 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL613755 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL1738023 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29389001 | 1.00 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL10259799 | 0.99 | EGFR (0.98) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93737 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93738 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4767093 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27585261 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2792 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260125490-A1 | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2026-05-07 | — | — | US | claimed |
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| EP-4673152-A2 | COMBINATIONS FOR TREATMENT OF PARKINSON'S DISEASE AND OTHER PRIMARY AND SECONDARY PARKINSONIAN DISORDERS | Kenai Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1416935-B1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | claimed |
| EP-1827437-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | Novartis AG (CH) | 2007-09-05 | — | — | EP | claimed |
| WO-2007082946-A1 | SOLID FORMS OF A PYRROLOPYRIMIDINE DERIVATIVE AND THEIR USE AS ANTI-TUMOR AGENTS | NOVARTIS AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7244729-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2007-07-17 | — | — | US | claimed |
| WO-2006065780-A2 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | claimed |